Pest control company Rollins (NYSE: ROL) will be reporting results this Wednesday afternoon. Here’s what you need to know.
Rollins met analysts’ revenue expectations last quarter, reporting revenues of $1.03 billion, up 12% year on year. It was a strong quarter for the company, with a solid beat of analysts’ adjusted operating income estimates and an impressive beat of analysts’ EBITDA estimates.
Is Rollins a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Rollins’s revenue to grow 11.5% year on year to $927.7 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.27 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Rollins has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Rollins’s peers in the environmental and facilities services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. BrightView delivered year-on-year revenue growth of 2.6%, beating analysts’ expectations by 4.2%, and Veralto reported revenues up 3.8%, falling short of estimates by 0.5%. BrightView traded down 7% following the results while Veralto was also down 6.2%.
Read our full analysis of BrightView’s results here and Veralto’s results here.
There has been positive sentiment among investors in the environmental and facilities services segment, with share prices up 8.2% on average over the last month. Rollins is up 6.1% during the same time and is heading into earnings with an average analyst price target of $65.28 (compared to the current share price of $64.71).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
